Halozyme Therapeutics, Inc. $HALO Shares Newly Purchased by Virtue Capital Management LLC

Key Points

• Virtue Capital Management acquired 12,270 Halozyme shares worth approximately $1.36 million, while institutional investors collectively own 97.79% of the company.
• Analyst sentiment is favorable, with Halozyme receiving a “Moderate Buy” consensus rating and an average price target of $99.55; recent targets range as high as $130.
• Halozyme recently exceeded quarterly earnings and revenue expectations, reporting $2.28 in EPS and $481 million in revenue, while insiders have sold approximately $13.5 million of stock over the past three months.

Virtue Capital Management LLC acquired a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 12,270 shares of the biopharmaceutical company's stock, valued at approximately $1,355,000.

Several other large investors have also bought and sold shares of HALO. Congress Asset Management Co. raised its position in shares of Halozyme Therapeutics by 85.6% in the 3rd quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company's stock worth $251,890,000 after acquiring an additional 1,052,509 shares in the last quarter. Bank of America Corp DE purchased a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at approximately $214,504,000. William Blair Investment Management LLC bought a new stake in shares of Halozyme Therapeutics during the second quarter valued at approximately $196,540,000. Royal London Asset Management Ltd. boosted its position in shares of Halozyme Therapeutics by 12.4% during the second quarter. Royal London Asset Management Ltd. now owns 1,810,815 shares of the biopharmaceutical company's stock valued at $141,732,000 after purchasing an additional 200,262 shares in the last quarter. Finally, Jupiter Topco LLC bought a new stake in shares of Halozyme Therapeutics during the second quarter valued at approximately $105,570,000. 97.79% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

HALO has been the topic of several recent research reports. JPMorgan Chase & Co. upped their price target on Halozyme Therapeutics from $70.00 to $78.00 and gave the stock a "neutral" rating in a research note on Thursday, October 8th. Leerink Partners raised Halozyme Therapeutics from a "market perform" rating to an "outperform" rating and raised their price objective for the company from $83.00 to $110.00 in a research report on Friday, August 7th. Benchmark restated a "buy" rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Wells Fargo & Company upped their target price on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an "equal weight" rating in a research report on Friday, August 7th. Finally, TD Cowen increased their price target on shares of Halozyme Therapeutics from $105.00 to $130.00 and gave the stock a "buy" rating in a research note on Tuesday, October 13th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Halozyme Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $99.55.

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $130.91 on Monday. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. The business's 50 day moving average price is $113.70 and its 200-day moving average price is $83.45. Halozyme Therapeutics, Inc. has a 52 week low of $61.22 and a 52 week high of $134.00. The stock has a market cap of $14.86 billion, a P/E ratio of 39.08, a P/E/G ratio of 0.49 and a beta of 0.92.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating analysts' consensus estimates of $1.79 by $0.49. The company had revenue of $481.00 million during the quarter, compared to analyst estimates of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%. The firm's revenue for the quarter was up 47.7% on a year-over-year basis. During the same quarter last year, the company earned $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 8.31 earnings per share for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the firm's stock in a transaction on Thursday, October 8th. The stock was sold at an average price of $109.40, for a total transaction of $2,188,000.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at $83,995,132. This trade represents a 2.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of Halozyme Therapeutics stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $102.80, for a total value of $167,152.80. Following the completion of the transaction, the director directly owned 40,418 shares of the company's stock, valued at approximately $4,154,970.40. This represents a 3.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 125,852 shares of company stock valued at $13,538,046. Insiders own 2.50% of the company's stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company's primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.